IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Clinical Cancer Research Année : 2018

IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma

Résumé

Cholangiocarcinoma (CCA) is a desmoplastic tumor of the biliary tree in which epidermal growth factor receptor (EGFR) is overexpressed and contributes to cancer progression. Although, EGFR has been envisaged as a target for therapy, treatment with tyrosine kinase inhibitors (TKI) such as erlotinib did not provide therapeutic benefit in patients with CCA, emphasizing the need to investigate resistance mechanisms against EGFR inhibition.

Dates et versions

hal-01808092 , version 1 (05-06-2018)

Identifiants

Citer

Javier Vaquero, Cindy Lobe, Sylvana Tahraoui, Audrey Clapéron, Martine Mergey, et al.. IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma. Clinical Cancer Research, 2018, 24 (17), pp.4282-4296. ⟨10.1158/1078-0432.CCR-17-3725⟩. ⟨hal-01808092⟩
108 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More